14th World ADC San Diego 2023

Memo

The ADC renaissance has continued to dominate the oncology field throughout 2023, with the long-awaited approval of ImmunoGen's ELAHERE - the 9th ADC to be approved in just three years. To add to the excitement, this incredible breakthrough is the first ADC for platinum-resistant ovarian cancer, proving their potential for treatments beyond breast cancer. Whether you have just ventured into the ADC space or are an ADC guru, the 14th World ADC San Diego has got you covered. Accompanying you from early discovery to late-stage manufacturing and regulatory challenges, this meeting has been designed with one aim in mind: to maximize the therapeutic window of your ADC, and propel ADCs to become life-changing, front-line treatments for oncology patients. With over 800 world-leading ADC experts in attendance including Daiichi Sankyo, ImmunoGen, AbbVie, Gilead Sciences, and Seagen, this is set to be the biggest-ever convergence of the ADC community yet and you cannot afford to miss it! URLs:Tickets: https://go.evvnt.com/1730899-2?pid=5569 Brochure: https://go.evvnt.com/1730899-3?pid=5569 LinkedIn: https://go.evvnt.com/1730899-4?pid=5569 Twitter: https://go.evvnt.com/1730899-5?pid=5569  Date and Time: On Mon, Oct 16, 2023 ( 9:00 AM) - Thu, Oct 19, 2023 ( 4:00 PM) Venue details: Sheraton San Diego Hotel and Marina, 1380 Harbor Island Drive, San Diego, California, 92101, United States Prices:Drug Developer Pricing - Conference Only: USD 2899.00,Drug Developer Pricing - Conference + Seminar Day OR Workshop Day: USD 3998.00,Drug Developer Pricing - Conference + Seminar Day + Workshop Day: USD 5097.00,Academic Pricing - Conference Only: USD 2599.00,Academic Pricing - Conference + Seminar Day OR Workshop Day: USD 3498.00,Academic Pricing - Conference + Seminar Day + Workshop Day: USD 4397.00,Service Provider Pricing - Conference Only: USD 3799.00,Service Provider Pricing - Conference + Seminar Day OR Workshop Day: USD 4998.00,Service Provider Pricing - Conference + Seminar Day + Workshop Day: USD 6197.00 Speakers: Abbas El Sahili, Chief Executive Officer, Singzyme, Adam Palmer, Assistant Professor, Pharmacology, UCN, Adam Taylor, Senior Scientist, Defence Science and Technology Laboratory, Amita Patel, Associate Principal Scientist, Merck and Co, Amy Han, Executive Director, R and D, Regeneron, Andrea Hernandez Rojas, Scientist and Group Lead, In Vitro Biology, ADC Therapeutic Development, Zymeworks, Andrea Ngai, Senior Manager - Bioanalysis and Biomarkers, Amador Bioscience, Andreas Pahl, Chief Scientific Officer, Heidelberg Pharma, Aniko Palfi, Director, Heidelberg Pharma Research, Anita Kulukian, Principal Scientist, Seagen, Atul Asati, Associate Director, Gilead Sciences, Benjamin Oshrine, Medical Director, Clinical Development, ImmunoGen, Changshou Gao, Senior Vice President and Chief Technology Officer, Innovent Biologics, Christian Marsolais, Senior Vice President and Chief Medical Officer, Theratechnologies, Christoph Antz, Chief Executive Officer, Veraxa Biotech, Christopher Marvin, Principal Research Scientist II, AbbVie, Christopher Shelton, Senior Vice President and Global Head of Business Development, GlaxoSmithKline, Chunze Li, Head of Oncology, Clinical Development, Genentech, Conor Barry, Head of Development, Piramal Pharma Solutions, Daniel Custar, Director, Drug Substance CMC, Mersana Therapeutics, David Bramhill, President and Founder, Bramhill Biological Consulting, Dharti Kothari, Associate Director - External Manufacturing, Chemistry, Manufacturing, Controls, Drug Substance and Drug Product, Bolt Biotherapeutics, Dolon Maji, Senior Scientist II, Drug Metabolism and Pharmacokinetics, AbbVie, Douglas Watson, Director, Regulatory Affairs CMC Biologics, Merck and Co, Earl Albone, Executive Director, Biochemistry and Bioanalytical Development, Eisai, Engin Ayturk, Executive Director, CMC Process Engineering and BioConjugation Development, Mersana Therapeutics, Eric Lacoste, Head of ADC Conjugation Development, Sanofi, Eshita Khera, Principal Scientist I, Novartis, Esohe Idusogie, Head of Process Quality and CMC Analytical, ADC Therapeutics, Esther Biemans, Senior Scientist, Ardena, Frank Comer, Director, Tumor Targeted Delivery, Early Oncology Discovery, AstraZeneca, Gang Yin, Vice President, Protein Biochemistry, Sutro Biopharma, Gerold Meinhardt, Vice President - Asset and Portfolio Management, Daiichi Sankyo, Giorgio Salciarini, Senior Manager - Technical Business Development, BSP Pharmaceuticals, Greg Thurber, Associate Chair, University of Michigan, Gregory Adams, Chief Scientific Officer, Elucidia Oncology, Guifeng Jiang, Head of Analytical Development, Bolt Biotherapeutics, Guitao Wang, President of R and D Institute, Coherent Biopharma, Guoxiang Shen, Executive Director, Head of Clinical Pharmacology, BioAtla, Hongling Han, Senior Director, Analytical Chemistry, Mersana Therapeutics, Hui Zhao, Senior Director, Translational Biology, Exelixis, James Palacino, Vice President and Head of Biology, Orum Therapeutics, James Purcell, Research Fellow, AbbVie, Jan Schnitzer, Founder, Director and Chief Executive Officer, PRISM Therapeutics, Jay Harper, Director, Early Oncology, AstraZeneca, Jesús Fuentes Antrás, Clinical Research Fellow, Princess Margaret Cancer Centre, Jia He, Senior Research Analyst, Beacon Targeted Therapies, Jian Chen, Director, Translational Research and Preclinical Development, BioAtla, Jianzhong Wen, Principal Scientist, Merck and Co, Jimmy Li, Chief Executive Officer, WuXi XDC, John DaSilva, Associate Director, Oncology and Angiogenesis, Regeneron Pharmaceuticals, John Lambert, Independent Consultant, Attager Consulting, Julie Beaudet, CMC Staff Scientist, Regeneron Pharmaceuticals, Juma Bridgewater, Principal Scientist, Amgen, Jun Hasewga, Scientist, Daiichi Sankyo, Jutta Deckert, Executive Director, Translational R and D, Iksuda Therapeutics, Kati Räsänen, Director, Pharmacology, SOTIO Biotech, Kimberly Gauthier, Director, Project Management, Merck and Co, Krishna Bajjuri, Senior Director, Chemistry, Sutro Biopharma, Kristin Bedard, Senior Vice President, Drug Discovery, Sutro Biopharma, Lara McGrath, Director Translational Medicine, AstraZeneca, Laurence Madera, Senior Scientist, In Vitro Biology, ADC Therapeutic Development, Zymeworks, Luke Masterson, Chemistry Group Leader, AstraZeneca, Manoj Chiney, Director, Clinical Pharmacology, Gilead Sciences, Marcia Belvin, Senior Vice President, Head of Research, CytomX Therapeutics, Martina McDermott, Adjunct Assistant Professor, University of California, Los Angeles, Meijuan Li, Vice President and Head of Biostatistics and Translational Science and Oncology, Eisai, Melanie Frigault, Vice President Translational Medicine, Vincerx Pharma, Michael Method, Executive Medical Director, ImmunoGen, Mike Liao, Global Clinical Oncology Lead, Genentech, Mingyan Cao, Associate Director, GlaxoSmithKline, Naresh Jain, President and Chief Executive Officer, NJ Bio, Nathan Ilhe, Senior Vice President, Bolt Biotherapeutics, Nicolas Camper, Senior Director, Bioconjugation Chemistry, Abzena, Patrick Groothuis, Principal Scientist, Byondis, Patrick Zweidler-McKay, Executive Medical Director, ImmunoGen, Paul Song, Chief Scientific Officer, Genequantum Healthcare, Philip Vitorino, Director, Head of Stromal Biology, Bristol Myers Squibb, Puja Sapra, Senior Vice President, Head R and D Biologics Engineering and Head Oncology Targeted Delivery, AstraZeneca, Radhika Balasubramani, Director, Technical Product Lead, Antibody Drug Conjugates, Merck and Co, Rakesh Dixit Co-founder, President and Chief Executive Officer, Bionavigen, Ramana Dopplapudi, Vice President, Avidity Biosciences, Robert Huang, Founder and Chief Executive Officer, Coherent Biopharma, Robert Lawrence, Principal Scientist, Seagen, Robert Lutz, Chief Scientific Officer, Iksuda Therapeutics, Ronald Elgersma, Project Manager, Byondis, Rui Fang, Associate Principal Scientist, M and D, Sam Bandel, Associate Director, External Manufacturing, Gilead Sciences, Samuele Cazzamalli, Head of Small Molecule Therapeutics, Philochem, Sarah Owen, Senior Scientist, Seagen, Sarah-Jane Neuberth, Group Leader In Vivo Biology, Heidelberg Pharma, Shalom Goldberg, Senior Principal Scientist, Johnson and Johnson, Shawn Zhang, Chief Scientific Officer, Ambrx Therapeutics, Shiyue Zhou, Senior Scientist, AbbVie, Shumin Liu, Chief Executive Officer, Shenzhen Enduring, Shunsuke Ozaki, Principal Scientist, Eisai, Sofia Genta, Medical Oncology Clinical Fellow, Princess Margaret Cancer Centre, Srinath Thirumalairajan, Director of Process Engineering, Seagen, Susan Solomon, Head of Quality Control, ADC Therapeutics, Tae Kyo Park, Chief Executive Officer, IntoCell